Open Access
Issue |
Natl Sci Open
Volume 2, Number 5, 2023
Special Topic: Gene Editing towards Translation
|
|
---|---|---|
Article Number | 20220070 | |
Number of page(s) | 6 | |
Section | Life Sciences and Medicine | |
DOI | https://doi.org/10.1360/nso/20220070 | |
Published online | 01 August 2023 |
- Katti A, Diaz BJ, Caragine CM, et al. CRISPR in cancer biology and therapy. Nat Rev Cancer 2022; 22: 259-279. [Article] [CrossRef] [PubMed] [Google Scholar]
- Li G, Li X, Zhuang S, et al. Gene editing and its applications in biomedicine. Sci China Life Sci 2022; 65: 660-700. [Article] [CrossRef] [PubMed] [Google Scholar]
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 2017; 377: 2531-2544. [Article] [CrossRef] [PubMed] [Google Scholar]
- Delhove JMKM, Qasim W. Genome-edited T cell therapies. Curr Stem Cell Rep 2017; 3: 124-136. [Article] [CrossRef] [PubMed] [Google Scholar]
- Carnevale J, Shifrut E, Kale N, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 2022; 609: 174-182. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
- Chen Z, Arai E, Khan O, et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 2021; 184: 1262-1280.e22. [Article] [CrossRef] [PubMed] [Google Scholar]
- Kumar S, Zeng Z, Bagati A, et al. CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells. Cancer Discov 2021; 11: 2050-2071. [Article] [CrossRef] [PubMed] [Google Scholar]
- Ye L, Park JJ, Peng L, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab 2022; 34: 595-614.e14. [Article] [CrossRef] [PubMed] [Google Scholar]
- Legut M, Gajic Z, Guarino M, et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 2022; 603: 728-735. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
- Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016; 126: 3130-3144. [Article] [CrossRef] [PubMed] [Google Scholar]
- Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020; 367[Article] [CrossRef] [PubMed] [Google Scholar]
- Wang Z, Li N, Feng K, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol 2021; 18: 2188-2198. [Article] [CrossRef] [PubMed] [Google Scholar]
- Si J, Shi X, Sun S, et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell 2020; 38: 551-566.e11. [Article] [CrossRef] [PubMed] [Google Scholar]
- Wiede F, Lu KH, Du X, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov 2022; 12: 752-773. [Article] [CrossRef] [PubMed] [Google Scholar]
- Zhao B, Gong W, Ma A, et al. SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. Nat Immunol 2022; 23: 1588-1599. [Article] [CrossRef] [PubMed] [Google Scholar]
- Yi Y, Chai X, Zheng L, et al. CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. Cell Discov 2021; 7: 27. [Article] [CrossRef] [PubMed] [Google Scholar]
- Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113-117. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
- Sachdeva M, Busser BW, Temburni S, et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat Commun 2019; 10: 5100. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
- Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy. Mol Ther-Methods Clin Dev 2017; 4: 92-101. [Article] [Google Scholar]
- Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 2020; 396: 1885-1894. [Article] [Google Scholar]
- Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res 2021; 27: 2764-2772. [Article] [CrossRef] [PubMed] [Google Scholar]
- Jo S, Das S, Williams A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun 2022; 13: 3453. [Article] [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
- Hu Y, Zhou Y, Zhang M, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res 2022; 32: 995-1007. [Article] [CrossRef] [PubMed] [Google Scholar]
- Jin G, Chang Y, Harris JD, et al. Adoptive immunotherapy: A human pluripotent stem cell perspective. Cells Tissues Organs 2023; 1-29. [Article] [CrossRef] [Google Scholar]
- Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 2022; 609: 369-374. [Article] [CrossRef] [PubMed] [Google Scholar]
- Ling X, Chang L, Chen H, et al. Improving the efficiency of CRISPR-Cas12a-based genome editing with site-specific covalent Cas12a-crRNA conjugates. Mol Cell 2021; 81: 4747-4756.e7. [Article] [Google Scholar]
- Sheridan C. Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare. Nat Biotechnol 2022; 40: 5-8. [Article] [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.